Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.

PMID:
29437040
2.

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.

Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK.

J Immunother Cancer. 2018 Jan 22;6(1):5. doi: 10.1186/s40425-018-0315-0.

3.

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.

Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, Choueiri TK.

J Immunother Cancer. 2017 Aug 15;5(1):66. doi: 10.1186/s40425-017-0273-y.

Supplemental Content

Loading ...
Support Center